VTGN: Vistagen Therapeutics Inc. Company Profile & Statistics

About

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Info & Links

CEO

Shawn K. Singh

Headquarters

343 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Auditor

WithumSmith & Brown, PC

Share holders

365

Employees

Vistagen Therapeutics Inc. Statistics

Valuation Measures

Market Capitalization²

64.59M

Enterprise Value

-19.66M

Enterprise Value/EBITDA(ttm)

0.43

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

77.32

Price to Book(mrq)

0.71

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-4521.71%

Profit Margin(ttm)

-6555.44%

Return on Equity(ttm)

-36.35%

Return on Invested Capital(ttm)

-37.66%

Return on Assets(ttm)

-33.62%

Income Statement

Revenue(ttm)

876.00K

Revenue Per Share(ttm)

0.03

Gross Profit(ttm)

876.00K

EBITDA(ttm)³

-45.62M

Net Income Available to Common(ttm)

-39.57M

Diluted EPS(ttm)

-1.24

Share Statistics

Beta (5Y Monthly)

0.82

52-Week Change

-44.10%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

27.84M

Dividend Yield

0.00%

Float⁴

27.48M

% Held by Insiders

1.29%

% Held by Institutions

78.39%

Balance Sheet

Total Cash(mrq)

97.58M

Total Cash Per Share(mrq)

3.50

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

13.29%

Quick Ratio(mrq)

13.29%

Book Value Per Share(mrq)

3.44

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.71

Free Cash Flow(ytd)

-21.86M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

VTGN

Vistagen Therapeutics Inc.

Vistagen Therapeutics Inc. Profile